Weight-loss drug manufacturer Novo Nordisk cuts 9000 jobs — and its profit forecast

Novo Nordisk, grappling with a 45% YTD share price decline and increased competition, announced a major operational restructuring under new CEO Mike Doustdar, including 9,000 job cuts (11% of its workforce) and DKK 8 billion ($1.2 billion) in cost savings by 2026. This move, aimed at streamlining operations and reallocating resources to core diabetes and obesity segments after rapid growth, has led to a revised 2025 operating profit growth forecast from 10-16% down to 4-10%, offset by immediate DKK 8 billion restructuring costs. While the stock initially recovered, analysts express skepticism, anticipating potential downgrades as investors await a more detailed growth strategy.

Analysis

Novo Nordisk is undertaking a significant operational restructuring under new CEO Mike Doustdar in response to a 45% year-to-date share price decline, intensified competition from Eli Lilly and others, and a recent profit warning. The plan involves cutting 9,000 jobs, or 11% of the workforce, to achieve DKK 8 billion in cost savings by 2026. This strategic reset, described as a "kitchen-sinking" effort, aims to streamline the organization after rapid growth from its Ozempic and Wegovy drugs led to increased complexity. However, the move comes with a substantial immediate cost, as an DKK 8 billion restructuring charge will be incurred next quarter. This has forced the company to slash its full-year 2025 operating profit growth guidance from 10-16% to 4-10%. While the market showed a slight recovery on the news, suggesting some investors believe the bad news is now priced in, analyst sentiment remains skeptical. As highlighted by UBS, the key uncertainty is when the reinvestment of savings will benefit the top line. The lowered guidance is expected to trigger a wave of downgrades from brokers, likely pulling the mean analyst price target of DKK 463 significantly lower.

Key Decisions for Investors

• Investors should immediately re-evaluate valuation models to reflect the sharply reduced 2025 operating profit growth guidance of 4-10% and the DKK 8 billion in near-term restructuring costs.
• It is critical to monitor for management's forthcoming detailed growth and reinvestment plan, as the current lack of clarity is a primary source of analyst skepticism and a key overhang on the stock.
• Anticipate near-term share price volatility as analysts adjust price targets downward from the current DKK 463 mean, and consider that Novo's internal focus may cede a competitive advantage to rivals like Eli Lilly during this restructuring period.